At a glance
ClinicalIndex Comparison Record- ✓Able to speak and read English
- ✓Between ages 21 and 55 years
- ✓At least one binge drinking episode per NIAAA definition in last 30 days
- ✓Moderate or severe DSM-5 AUD based on computerized SCID
- ✕Seeking treatment at time of study
- ✕Contraindications or allergies to suvorexant
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Influence of Orexin Antagonism on Motivation for Alcohol
In Brief
A Early Phase 1 clinical trial evaluating Alcohol, Placebo, and 1 other intervention for Alcohol Use Disorder. Currently recruiting, targeting 30 participants across 1 site.
Detailed Summary
This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.
Study Details
Timeline
Arms & Interventions
Subjects will be treated daily with an oral placebo.
Subjects will be treated daily with oral suvorexant (10 mg).
Subjects will be treated daily with oral suvorexant (20 mg).
Interventions
The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
The effects of placebo will be determined.
The effects of suvorexant dose 1 will be determined.
The effects of suvorexant dose 2 will be determined.